- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03061838
Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®
Multicenter Double-blind Randomized Clinical Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Biosimilar Drug Ritumax® Compared to Original Drug MabThera® in Patients With Rheumatoid Arthritis
This is a multicenter, double-blind, randomized clinical study of safety, tolerability, pharmacokinetics and pharmacodynamics of biosimilar drug Ritumax® compared to original drug MabThera® in patients with rheumatoid arthritis, receiving stable doses of Methotrexate.
At Week -2, after signing the Patient Information Sheet and Informed Consent Form, patients with rheumatoid arthritis receiving stable doses of Methotrexate (10-25 mg per week orally or parenterally) will pass screening procedures.
Patients meeting all the inclusion/exclusion criteria will be invited to the investigational site for Visit 2 (Week 0) to be randomized into one of two treatment arms:
- Ritumax® 1000 mg х 2 intravenous infusions
- MabThera® 1000 mg х 2 intravenous infusions After being assigned to the treatment arm patients will receive a course of study treatment, including two i/v infusions at 14-day interval: at Week 0 and Week 2.
After that, patients will be followed up for the next 22 weeks. Safety, pharmacokinetic and pharmacodynamic parameters will be monitored at this visits.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation, 115522
- Federal State Budgetary Institution "Scientific Research Institution of Rheumatology" Russian Academy of Medical Sciences (FSBI "SRIR" RAMS)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Patient Information Sheet and Informed Consent Form to participate in the study.
- Men and women aged 18 years and older.
- Patient diagnosed with rheumatoid arthritis of at least 6-month duration, determined according to classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) (ACR-EULAR 2010) or the American College of Rheumatology (ACR1987) (in case if the diagnosis of rheumatoid arthritis was determined till 2010).
Active phase of the disease confirmed due to the combination of the following parameters:
- DAS28 > 3,2
- 5 (of 28) of tender and 5 (of 28) of swollen joints
- CRP level ≥1,5 mg/dL and/or ESR > 28 mm/h
- positive test for rheumatoid factor and/or CCP antibodies
- Patients with negative response to or intolerability to the DMARD therapy.
Current outpatient therapy of rheumatoid arthritis:
- continuous therapy with Methotrexate for at least 12 weeks prior to screening
- stable doses of Methotrexate (10-25 mg per week) within 4 weeks prior to screening
- when currently under the corticosteroids therapy, the dose should be stable within the last 4 weeks prior to screening and be less than 10 mg of Prednisolone or its equivalent
- when currently under the NSAID therapy, the dose should be stable within the last 4 weeks prior to screening
Exclusion Criteria:
The patient will be deemed ineligible for the study meeting any of the following criteria:
- Other inflammatory arthropathies apart from rheumatoid arthritis (e.g. gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme desease) or other system autoimmune diseases (e.g. systemic lupus erythematosus, inflammatory bowel disease, pneumosclerosis or Felly's syndrome, sclerodermia, inflammatory myopathy, mixed collagenosis or other crossed syndrome). Patients with secondary Sjorgen's syndrome or secondary limited cutaneous vasculitis with a rheumatoid arthritis background may participate in the study.
- Chronic heart failure Class III or IV in New York Heart Association (NYHA) classification and clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation).
- Serious chronic pulmonary diseases (COPD, bronchial asthma); functional dyspnea of severity level III and higher (due to the Medical Science Research Council scale for dyspnea).
- Signs of significant uncontrolled concomitant disease, e.g. renal, hepatic, gastrointestinal, endocrine system and nervous system disorders, which, according to the Investigator's opinion, could prevent the patient's participation in the study.
- Any surgical procedure, including bone and joint surgeries, or synovectomy (including arthrodesis or endoprosthesis replacement), performed within 12 weeks prior to screening or planned to be performed within 24 weeks after (except for small surgical procedures, requiring a local anesthesia or no anesthesia).
- Infectious diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: MabThera®
2 intravenous infusions on Week 0 and Week 2 (14-day interval).
|
1000 mg intravenously
Other Names:
|
EXPERIMENTAL: Ritumax®
2 intravenous infusions on Week 0 and Week 2 (14-day interval).
|
1000 mg intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration versus time curve (AUC)
Time Frame: within a 24-week period
|
Comparative assessment of pharmacokinetic parameters of Ritumax® and MabThera
|
within a 24-week period
|
Peak Plasma Concentration (Cmax)
Time Frame: within a 24-week period
|
Comparative assessment of pharmacokinetic parameters of Ritumax® and MabThera
|
within a 24-week period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CD19+ B- lymphocytes
Time Frame: within a 24-week period
|
Comparative assessment of pharmacodynamic parameters of Ritumax® and MabThera®
|
within a 24-week period
|
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability).
Time Frame: within a 24-week period
|
The number of patients with treatment-related AEs
|
within a 24-week period
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- ONCRA-RXM-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on MabThera®
-
Assistance Publique - Hôpitaux de ParisHoffmann-La RocheCompleted
-
Alexion PharmaceuticalsPortola PharmaceuticalsCompletedFollicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)United States
-
Hoffmann-La RocheCompletedNon-Hodgkin's LymphomaMacedonia, The Former Yugoslav Republic of
-
Boehringer IngelheimTerminatedArthritis, RheumatoidUnited States, United Kingdom, Netherlands, Ireland, Argentina, Poland, Mexico, Spain, Bulgaria, Chile, Germany, Ukraine, Portugal, Belgium, Canada, Greece, Hungary
-
Charite University, Berlin, GermanyUnknownFollicular Lymphoma
-
University Hospital, ToulouseCompletedCryoglobulinemia | Cold Agglutinin Disease | Pemphigus | Auto-immune Thrombocytopenic Purpura | Hemolytic Auto-immune AnaemiaFrance
-
University of CopenhagenRigshospitalet, DenmarkCompletedFatigue | Keratoconjunctivitis Sicca | Primary Sjögren's Syndrome | Xerostomia | HyposalivationDenmark
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedFollicular LymphomaGermany
-
AmgenCompletedArthritis, RheumatoidUnited States, Germany, Bulgaria, Hungary, Poland, Estonia